Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
델타의 중화 감소 (B.1.617.2) 예방 접종 후 SARS-COV-2 우려 변형
Research Article
[키워드] (Beta
accumulation
African
antibody
Antibody titre
antigenic
antigenic drift
antigenic profiles
assessment
Astra Zeneca
Author
B.1.351
B.1.617.1
B.1.617.2
bat
bats
Beta
BNT162b2
BNT162b2 vaccines
Booster vaccine
booster vaccines
ChAdOx1
changes in
collected
COVID-19
COVID19
death
decrease
decreases
Delta
delta variant
dose
effective
Effectiveness
Efficacy
elicited
evade
expressed
facilitate
fold
Fold changes
glycoprotein
groups
hospitalisation
Human
human cell
human cells
humans
Immunity
India
indicated
individual
Infection
Lineage
magnitude
Mutation
neutralisation
neutralise
Neutralising Antibodies
neutralising antibody titres
of BNT162b2
Pfizer
Pfizer/BioNTech
Prevent
profile
protective immune response
pseudoviruses
recipient
recipients
reduced
reduction
reduction in
reductions
reductions in
required
risk
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 variant
SARS-CoV-2 variants
SARS-CoV-2 virus
sensitivity
sera
Severe infection
shape
significantly higher
South
South Africa
spike glycoprotein
spike glycoproteins
Spike protein
subsequent
the spike protein
titre
vaccinated individuals
vaccination
Vaccine
vaccine efficacy
Vaccines
variant
variant B.1.617.2
variants
variants of concern
Viral
viral variant
Viral variants
virus
Virus spike
VOCs
while
with infection
with infections
Wuhan
Wuhan, China
[DOI] 10.1371/journal.ppat.1010022 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.ppat.1010022 PMC 바로가기 [Article Type] Research Article